Showing results (611-620 of 3,353) with videos related to

Sort By:
Pageof 336
The Lancet. Oncology|December 3, 2020
Addition of chemotherapy to local therapy in women aged 70 years or older with triple-negative breast cancer: a propensity-matched analysisJennifer A Crozier, Todd A Pezzi, Caitlin Hodge, et al.
The Lancet. Oncology|December 3, 2020
Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine TrialCarolina Porras, Sabrina H Tsang, Rolando Herrero, et al.
The Lancet. Oncology|December 7, 2020
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trialThomas Powles, Elizabeth R Plimack, Denis Soulières, et al.
The Lancet. Oncology|November 30, 2020
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trialStephen A Boorjian, Mehrdad Alemozaffar, Badrinath R Konety, et al.
The Lancet. Oncology|January 2, 2021
Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolboxPeter Dubsky, Katja Pinker, Fatima Cardoso, et al.
The Lancet. Oncology|January 2, 2021
The genomic landscape of breast cancer brain metastases: a systematic reviewAlexander J Morgan, Athina Giannoudis, Carlo Palmieri
The Lancet. Oncology|December 28, 2020
Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trialRobert D Morgan, Iain A McNeish, Adrian D Cook, et al.
The Lancet. Oncology|July 8, 2021
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trialMarcia S Brose, Bruce Robinson, Steven I Sherman, et al.
The Lancet. Oncology|June 10, 2021
Variation in the risk of colorectal cancer in families with Lynch syndrome: a retrospective cohort study
The Lancet. Oncology|November 1, 2020
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trialShaji K Kumar, Simon J Harrison, Michele Cavo, et al.
Pageof 336